This study is a single-centre, two-arm, parallel group Randomized Controlled Trial (RCT) to test the effectiveness, safety, impact of device application on health-related quality of life measures, and cost-effectiveness of ClearGuard™ HD antimicrobial barrier caps in patients receiving hemodialysis.
Setting and Sample:
The ECHO-HD will be undertaken at the Metro North Kidney Health Service (MNKHS), Royal Brisbane and Women's Hospital in Queensland, Australia.
Sample Size:
The investigators will recruit 60 patients with 30 patients per arm. The purpose of the pilot study is to assess research project feasibility and inform the design of a large scale powered RCT. Viechtbauer et al. (2015) determined that a sample size of 59 participants is sufficient to detect a problem with a 5% probability of occurrence.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age≥18
Able to provide informed consent
Kidney failure requiring a tunnelled CVC for treatment (haemodialysis)
21 days BSI free
No known allergy to chlorhexidine and/or nylon and/or polypropylene.
You may not be if
Current CLABSI
Known allergic to chlorhexidine and/or nylon and/or polypropylene.
Patients on an end-of-life pathway
People with a cognitive impairment and/or intellectual disability